Collagen Solutions PlcJamal Rushdy, CEO

Company OverviewApril, 2017

DisclaimerThis presentation is incomplete without reference to, and should be viewed solely in conjunction with the oral briefing which accompanies it.The information in this presentation is subject to updating, revision and amendment. The information in this presentation, which includescertain information drawn from public sources does not purport to be comprehensive and has not been independently verified. Thispresentation has not been examined, reviewed or compiled by the Company’s independent certified accountants.

No reliance may be placed for any purpose whatsoever on the information contained in this presentation or any assumptions made as to itscompleteness. No representation or warranty, express or implied, is given by the Company, any of its subsidiaries or any of its advisors,directors, officers, employees or agents, as to the accuracy, reliability or completeness of the information or opinions contained in thispresentation or in any revision of the presentation or of any other written or oral information made or to be made available to any informationor opinions (which should not be relied upon) and no responsibility is accepted for any errors, misstatements in or omissions from thispresentation or for any loss howsoever arising, directly or indirectly, from any use of this presentation or its contents. The information andopinions contained in this presentation are provided as at the date of this presentation and are subject to change without notice.

In particular, this presentation may contain certain forward looking statements that are subject to the usual risk factors. Whilst the Companybelieves the expectations reflected herein to be reasonable in light of the information available to them at this time, the actual outcome maybe materially different owing to factors beyond the Company’s control or with in the Company’s control where, for example the Companydecides on a change of strategy. Accordingly no reliance may be placed on the figures or other indications contained in any such potentialforward-looking statements. No representation or warranty of any kind is made with respect to the accuracy or completeness of the financialprojections or other forward looking statements, any assumptions underlying them, the future operations or the amount of any future incomeor loss.

The content of this presentation has not been approved by an authorised person within the meaning of the Financial Services and MarketsAct 2000 (“FSMA”). This presentation does not constitute or form part of any offer or invitation to see, or any solicitation of any offer topurchase or subscribe for or otherwise acquire, any securities in the Company in any jurisdiction or any other body corporation or aninvitation or an inducement to engage in investment activity under section 21 of FSMA, nor shall it or any part of it form the basis of or berelied on in connection with any contract therefore. This presentation does not constitute an invitation to effect any transaction with theCompany or to make use of any services provided by the Company. Reliance on the information contained in this presentation for thepurposes of engaging in any investment activity may expose the investor to a significant risk of losing all of the property or assets invested.Any person who is in any doubt about the investment to which this presentation relates should consult a person duly authorised for thepurposes of FSMA who specialises in the acquisition of shares and other securities.

By attending the presentation, or reading or accepting this document you agree to be bound by the foregoing limitations.

April 2017 2

Overview

Opportunity Multiple growth initiatives create potential for 5x+ revenue within 5 years

Strategy & Value

CreationCore Business + Finished Device Pipeline creates multiple value creation opportunities

Core Business Stable recurring sales from collagen and tissue-based biomaterials and devices

Finished Device

PipelinePipeline of finished devices with owned I.P. for commercialisation via distribution and licensing

Growth Recently reported 6 month interim results £1.9m sales/other income, +30% on prior year

Stronger Balance Sheet Recent funding of up to £10.8m provides funding path to execute.

3

A Global Regenerative Biomaterials Company

• Founded in 2014, London Stock Exchange listed (COS)

• Operations in Minneapolis USA, Glasgow UK, Marton NZ

• Sales office in Seoul, South Korea; JV in Beijing, China

• Core business is supply, development, manufacturing of

collagen and tissue-based materials and medical devices

• Pipeline of finished devices for sale, license, distribution

Medical Grade Collagen Tissue (Pericardium)

Products used in cardiovascular, orthopedics, dental, wounds,

research, and other applications

Cartilage Wounds Bone

4

Collagen and Tissue Biomaterials

• Primary structural protein in tissues

• Provides physical support and a

conducive environment for cells

Collagen Tissue

• Pericardium tissue is processed into medical devices

• Example includes engineered heart valves

Using natural collagen proteins and tissue to engineer

regenerative biomaterials and medical devices

5

We address the “Tissue Engineering” space

• 700 companies; $3 billion invested in regenerative medicine

• Moving from mechanical replacement to regeneration

Old:

Metal and plastic

New & Now:

Re-grow the knee

6

Core Business Finished Devices

B2B supply, development, manufacturing of

collagen and tissue materials/medical devices

Novel proprietary medical devices for out-

licensing and distribution, and/or sale

Building Value in Two Ways

7

Core Biomaterials Business Drivers

Core Business Growth Model

• Development and prototypes → to supply and manufacturing

• Revenue is “sticky” → Switching costs are high

• New commercial team and distribution → Geographically expand

Drivers

• New commercial team and distribution agreements

• Geographic expansion in North America, Asia, Europe

• Near-term customer launches (e.g. heart valve, bone graft)

• JV in China recently validated with in-country shipments

• Research markets through distribution and on-line direct

• Pericardium tissue business and new tissue technologies

8

Competitive Landscape

• 8 primary competitors

• Several focused on end-markets, not supply

• Opportunities for COS partnerships with some

Our Competitive Advantage as validated by independent Voice of Customer interviews:

World Class Standards

Broad Range of Materials

Collaborative Approach

Customers value our sole focus on partner success based on our expertise in collagen and biomaterials

9

ChondroMimetic™

Cartilage Repair

Fibrillar Collagen

Wound Treatment

Bone Graft Substitutes

Bone Regeneration

• Previously used in Europe, 6+ years

evidence in patients

• Retro study and CE mark in process,

targeted for 1H 2017

• Potential 450,000 cartilage procedures

($500m-$1b+ potential market)

• Potential to address multiple markets in

wound care and burns

• Target wound market clearance in 2018

• Addresses c.40% of $1 billion market

• Provisional patent filed December, 2016

• Target orthopaedic market clearance in

2018

• Addresses c.30% of $1.7 billion market

Finished Device Pipeline

10

Multiple Growth Drivers

Sales channels, geographic expansion, OEM mix

Current finished device pipeline + licensing/distribution

Next stage pipeline + licensing/distribution

£0.1

£1.5 £1.9

£0.02

£1.0

£3.2

5x+

FY 2014 FY 2015 FY 2016 FY 2017

6 Mos Full YearSales and other income (millions)

11

Recently Strengthened Balance Sheet

• Q1 2017 financing of up to £10.8m• £6.8m equity raise via placement and open offer

• Up to £4.0m (£2.0m minimum) in private bonds with strategic partner, Norgine

• Norgine strategic partnership• 110 year-old private European specialist pharmaceutical company, €300m+ sales

• Venture arm invests in/acquires strategic pharmaceutical & device companies

• Partnership provides access to Norgine’s device/pharma expertise and resources

• Proceeds to fund product development and core business growth

12

Experienced Management Team

Jamal Rushdy, CEO• 20+ years medical devices, orthopaedics and biologics

• 2 public medical device companies, 3 successful start-ups• M&A, marketing, sales ops, finance

Management Team:

• Multiple successful exits for shareholders

• Specific domain knowledge of end-markets

• Deep collagen and tissue experience

Gill Black, CFO• 25+ years experience as CA with board-level financial experience

• Senior manager at KPMG leading high growth business team

Brad Selman, VP Global Sales & Marketing• 30+ years commercial, sales & marketing, business development

• Commercial roles Noble Biomaterials, Molnlycke, Coloplast

Stewart White PhD, CSO• Founding CEO, Collagen Solutions and Collbio• International operations, business and product development

Chris Wattengel, VP Global R&D• 16+ years biomaterials product development at Kensey Nash/DSM

• Multiple 510(k) and CE-marked product clearances

Tom Hyland, COO• 30+ years med tech operations + collagen expertise

• Johnson & Johnson, Life Technologies (Thermo Fisher Scientific)

Kevin Darling, GM New Zealand• 20+ years commercial, sales & marketing, operational

management

• Commercial roles with 3M (Medical), BOC Gases, Mars

13

Summary

• Multiple growth initiatives create potential for 5x+ revenue within 5 years

• Strategy provides for multiple value creation opportunities

• Solid foundation of consistent recurring sales

• Pipeline of finished devices in attractive markets

• Strengthened balance sheet + management team with value creation track record

14

Thank You

Appendix:Summary of Interim Results Six months ended 30 September 2016

16

Embedded customers driving revenue growth

£1.04mYear Ending

31 March 2015

£3.24mYear Ending

31 March 2016

Six month revenue & other income trend

£0.02 £0.14

£0.89

£1.46

£1.78

£1.89

31-Mar-14 30-Sep-14 31-Mar-15 30-Sep-15 31-Mar-16 30-Sep-16

17

Financial KPIs

£143,213

£1,460,218

£1,891,001

Revenue & Other Income (£)

30-Sep-14 30-Sep-15 30-Sep-16

£119,023

£1,090,856

£1,305,150

Gross Profit (£)

30-Sep-14 30-Sep-15 30-Sep-16

83.2%

75.7%

71.3%

Gross Margin (%)

30-Sep-14 30-Sep-15 30-Sep-16

83.2%

75.7%71.3%

Gross Margin (%)

18

Financial KPIs

*Before separately identifiable items:

• 2016: Unrealised translation losses on deferred consideration - £294,229 debit

• 2015: NIL

• 2014: NIL

(522,144)

(79,376)

(712,537)

LBITDA* (£)30-Sep-14 30-Sep-15 30-Sep-16

(0.88)

(0.26)

(0.60)

EPS (p)

30-Sep-14 30-Sep-15 30-Sep-16

927,094

3,104,230

1,657,193

Cash and Equivalents (£)

30-Sep-14 30-Sep-15 30-Sep-16

19

Revenue by geographic region

6 months ended 30 September

54%

10%

36%

2016 Revenue by region

North America EMEA Asia Pacific

59%

2%

39%

2015 Revenue by region

North America EMEA Asia Pacific

20

Revenue by activity

6 months ended 30 September

58%

7%

35%

2016 Revenue by activity

Contract Manufacturing Development Materials

64%7%

29%

2015 Revenue by activity

Contract Manufacturing Development Materials

21